Navigation Links
Strativa Pharmaceuticals' Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
Date:9/14/2009

WOODCLIFF LAKE, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat. The data from this study, the largest study to date conducted in OPC, were presented in an oral presentation to attendees at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. More than 10,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the problem of infectious diseases.

The randomized, double-blind, double-dummy study compared the efficacy and safety of once-daily miconazole 50 mg MBT to clotrimazole 10 mg troche administered five times per day for treatment of OPC. Results showed no significant differences between miconazole MBT and clotrimazole troches in any of the clinical efficacy endpoints, including the primary endpoint of complete resolution of signs and symptoms of OPC. The study was conducted in 577 HIV/AIDS patients in 40 sites in the United States, Canada and South Africa.

Miconazole MBT -- which delivers the antifungal miconazole via a mucoadhesive buccal tablet designed to enable once-daily dosing of the active ingredient at the site of infection -- is currently undergoing review by the U.S. Food and Drug Administration (FDA). If approved, Strativa, the exclusive U.S. distributor of miconazole MBT under a licensing agreement with BioAlliance Pha
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Strativa Pharmaceuticals Provides Product Pipeline Update
2. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
3. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
6. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
7. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
8. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
9. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
10. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
11. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... candidates targeting specific pathogens that cause serious infections and ... market activity in the Company,s stock, the NYSE MKT ... its usual practice. The Company stated that its policy ... About Synthetic Biologics, Inc. Synthetic Biologics, ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Surgical Navigation Systems Market ... Systems) - Global Industry Analysis, Size, Share, Growth, Trends ... systems market was valued at USD 218.5 million in ... of 4.5% from 2014 to 2020, to reach an ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... , DUBLIN, Ohio, Dec. 2 Cardinal Health today announced ... directors, effective immediately. , Cox, 52, most recently served as ... Corp. She completed her tenure with the company at the ... Prior to her term at Schering-Plough, Cox served as president ...
... , , ROCKVILLE, Md., Dec. 2 ... results from the first stage of a two-stage pivotal Phase ... 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax ... Mexico to support registration of the vaccine in Mexico and ...
Cached Medicine Technology:Cardinal Health Names Carrie Cox to Board of Directors 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... 29, 2014 The Law Offices of Michael ... of Hope, a non-profit organization providing grief camps for kids, ... anguish and suffering our clients experience from the death of ... support an organization like Stepping Stones of Hope, as they ... Stepping Stones of Hope also includes a monthly support group ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 During his 37 ... Bruce, DMD & Associates, has had a steady stream of ... dentistry. These students have now gone on to dental school ... proving that the shadowing program helps college students find success. ... Bruce has given them the chance to see a realistic ...
(Date:7/29/2014)... July 29, 2014 Summer is here, and that ... enjoying a hike, swimming in a pool or laying out on ... fleas and ticks. The Puppy Store is here to help pet ... months. , It’s almost impossible to completely keep fleas and ticks ... minimize the chances of their pets coming into contact with fleas ...
(Date:7/29/2014)... receive steady follow-up care, the living donors themselves ... care more accessible, UC San Francisco and Walgreens ... the first program in the country that provides ... kidney donors. , UCSF will provide vouchers for ... Walgreens pharmacies and Healthcare Clinic at select Walgreens ...
Breaking Medicine News(10 mins):Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Caring for donors 2Health News:Caring for donors 3
... seeks insights into chronic, illnesses, including heart failure and COPD, ... ... VENTURA, Calif., Oct. 8 VivoMetrics announced today,that noted researcher Bruce D. ... VivoMetrics LifeShirt(R) System to,the South Pole to collect valuable data for his ...
... Oct. 8 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ... as,senior vice president and chief commercial officer, effective ... NPS executive team, Mr. O,Callaghan will be,responsible for ... activities, including the commercial development of NPS,s,late-stage products ...
... The Physicians Coalition,for Injectable Safety today issued ... lipolysis or other injectable treatments touted to,reduce localized ... not,be mistaken as an accepted medical or cosmetic ... fat, using compounded pharmaceuticals, or,herbal agents, claim a ...
... the stories of eight mothers who survived ... breast ... product and baby gear brand, celebrates the "Power of Pink" by,announcing the ... Month, the eight outstanding women will be recognized,during the Susan G. Komen ...
... NEW YORK, Oct. 8 Health Management Systems,Inc. ... business of Peer Review,Systems, Inc. d/b/a/ Permedion, an ... in Westerville, Ohio. With this,acquisition, HMS augments its ... offerings for state Medicaid agencies and,managed care organizations. ...
... likely than whites to get tamoxifen, for example , , MONDAY, ... that has spread to the lymph nodes are less likely ... chemotherapy than white women with the same level of disease ... to the lymph nodes, we are seeing that African-American women ...
Cached Medicine News:Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 2Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 3Health News:NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer 2Health News:Consumer Safety Alert on Fat Dissolving Injections 2Health News:Consumer Safety Alert on Fat Dissolving Injections 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 2Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 4Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:Black Women Get Less Breast Cancer Treatment 2Health News:Black Women Get Less Breast Cancer Treatment 3
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: